1.12 is Alkermes Inc’s (NASDAQ:ALKS) Institutional Investor Sentiment

October 13, 2017 - By Winifred Garcia

 1.12 is Alkermes Inc's (NASDAQ:ALKS) Institutional Investor Sentiment

Sentiment for Alkermes Inc (NASDAQ:ALKS)

Alkermes Inc (NASDAQ:ALKS) institutional sentiment increased to 1.12 in Q2 2017. Its up 0.01, from 1.11 in 2017Q1. The ratio is better, as 118 investment managers increased or opened new holdings, while 105 cut down and sold their positions in Alkermes Inc. The investment managers in our partner’s database now own: 143.16 million shares, up from 140.52 million shares in 2017Q1. Also, the number of investment managers holding Alkermes Inc in their top 10 holdings decreased from 3 to 2 for a decrease of 1. Sold All: 33 Reduced: 72 Increased: 77 New Position: 41.

Alkermes plc is a biopharmaceutical company. The company has market cap of $7.73 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

The stock decreased 0.08% or $0.04 during the last trading session, reaching $50.29. About 384,813 shares traded. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since October 13, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Wall Street await Alkermes Plc (NASDAQ:ALKS) to release earnings on November, 1. Analysts forecast EPS of $-0.15, up exactly $0.10 or 40.00 % from 2014’s $-0.25 EPS. After posting $-0.13 EPS for the previous quarter, Alkermes Plc’s analysts now forecast 15.38 % negative EPS growth.

Meditor Group Ltd holds 8.99% of its portfolio in Alkermes Plc for 1.03 million shares. Opus Point Partners Management Llc owns 42,623 shares or 2.27% of their US portfolio. Moreover, Jag Capital Management Llc has 2.19% invested in the company for 188,682 shares. The New York-based Roanoke Asset Management Corp Ny has invested 2.09% in the stock. Kelly Lawrence W & Associates Inc Ca, a California-based fund reported 118,100 shares.#img1#

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Ratings analysis reveals 73% of Alkermes’s analysts are positive. Out of 11 Wall Street analysts rating Alkermes, 8 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $35 while the high is $85. The stock’s average target of $61.40 is 22.09% above today’s ($50.29) share price. ALKS was included in 26 notes of analysts from September 1, 2015. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Overweight” rating by Morgan Stanley on Tuesday, September 1. The stock has “Neutral” rating by UBS on Friday, January 22. As per Thursday, July 27, the company rating was maintained by Leerink Swann. The stock of Alkermes Plc (NASDAQ:ALKS) has “Buy” rating given on Tuesday, June 6 by Jefferies. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Overweight” rating by JP Morgan on Friday, October 21. The firm has “Buy” rating by Jefferies given on Thursday, August 24. The firm has “Outperform” rating by Leerink Swann given on Thursday, January 21. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, July 13. On Friday, October 21 the stock rating was maintained by Leerink Swann with “Outperform”. J.P. Morgan maintained Alkermes Plc (NASDAQ:ALKS) rating on Thursday, June 29. J.P. Morgan has “Buy” rating and $7800 target.

More news for Alkermes Plc (NASDAQ:ALKS) were recently published by: Seekingalpha.com, which released: “Alkermes Preliminary Phase 3 Data Leaves A Welcomed Impression” on July 05, 2017. Streetinsider.com‘s article titled: “Alkermes plc (ALKS) Says Patients Switched to its ARISTADA Showed Significant …” and published on September 18, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.